Torphasol vet (Morphasol) Stungulyf, lausn 10 mg/ml أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

torphasol vet (morphasol) stungulyf, lausn 10 mg/ml

animedica gmbh* - butorphanolum tartrat - stungulyf, lausn - 10 mg/ml

Metylfenidat Actavis Forðatafla 54 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

metylfenidat actavis forðatafla 54 mg

actavis group ptc ehf. - methylphenidatum hýdróklóríð - forðatafla - 54 mg

Cefotaxim Navamedic (Cefotaxim Villerton) Stungulyfsstofn, lausn 1 g أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

cefotaxim navamedic (cefotaxim villerton) stungulyfsstofn, lausn 1 g

navamedic asa - cefotaximum natríum - stungulyfsstofn, lausn - 1 g

Kåvepenin Frukt (Kåvepenin (mixt. 50 mg/ml)) Mixtúrukyrni, dreifa 50 mg/ml أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

kåvepenin frukt (kåvepenin (mixt. 50 mg/ml)) mixtúrukyrni, dreifa 50 mg/ml

viatris aps - phenoxymethylpenicillinum kalíum - mixtúrukyrni, dreifa - 50 mg/ml

Combisyn Stungulyf, dreifa 14,0/3,5 % w/v أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

combisyn stungulyf, dreifa 14,0/3,5 % w/v

norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - stungulyf, dreifa - 14,0/3,5 % w/v

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - blóðþurrðandi lyf - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). l hækkun, bráð myndun stíflufleygs, ásamt asa í læknisfræðilega sjúklingum rétt fyrir segaleysandi meðferð. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. nánari upplýsingar er að vísa til kafla 5.

Prevenar الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

prevenar

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - bóluefni - virk bólusetningar gegn sjúkdómum af völdum læknafélag bakteríusýkingum serotypes 4, 6b, 9v, 14, 18c, 19f og 23f (þar á meðal blóðeitrun, heilahimnubólga, lungnabólgu, bacteraemia og bráð eyrnabólga fjölmiðla) á börn frá tveimur mánuðum upp að fimm ára aldri. notkun prevenar ætti að vera ákveðin á grundvelli opinbera tillögur að taka tillit áhrif innrásar sjúkdóminn í mismunandi aldri tekur eins og l serotype faraldsfræði í mismunandi landsvæðum.

Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

adjupanrix (previously pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals)

glaxosmithkline biologicals s.a. - hættu inflúensuveiru, óvirkt, innihalda mótefnavaka: a / vietnam / 1194/2004 (h5n1) eins og álag notað (nibrg-14) - influenza, human; immunization; disease outbreaks - bóluefni - fyrirbyggjandi inflúensu í opinberlega lýst faraldur ástandið. bólusetning gegn heimsfaraldri inflúensu ætti að nota í samræmi við opinbera leiðbeiningar.

Aftovaxpur DOE الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

aftovaxpur doe

boehringer ingelheim vetmedica gmbh - hámarks þrjú eftirfarandi hreinsað, óvirkur gin-og klaufaveiki veira stofnar: o1 verkir stærri 6 pd50*; o1 bfs stÆrri 6 pd50*; o taívan 3/97 stærri 6 pd50*; a22 Írak stærri 6 pd50*; a24 sao stærri 6 pd50*; kalkúnn 14/98 stærri 6 pd50*; asíu 1 shamir stærri 6 pd50*; sat2 sádi-arabíu sem stóð 6 pd50*; * pd50 – 50% verndandi skammt í nautgripum eins og lýst er í doktor evra. fræðilega 0063. - Ónæmisfræðilegar upplýsingar - pigs; cattle; sheep - virk ónæmisaðgerð nautgripa, sauðfjár og svína frá 2 vikna aldri gegn gin- og klaufaveiki til að draga úr klínískum einkennum.

Ixiaro الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

ixiaro

valneva austria gmbh - japanska heilabólguveiru, óvirkt (dregið álag sa14-14-2 vaxið í veró frumum) - encephalitis, japanese; immunization - bóluefni - ixiaro er ætlað til virkrar bólusetningar gegn japanska heilabólgu hjá fullorðnum, unglingum, börnum og ungbörnum á aldrinum tveggja mánaða og eldri. ixiaro ætti að vera talin til að nota í einstaklinga á hættuna af völdum í gegnum ferðast eða í tengslum þeirra starf.